JP2023526224A5 - - Google Patents
Info
- Publication number
- JP2023526224A5 JP2023526224A5 JP2022568713A JP2022568713A JP2023526224A5 JP 2023526224 A5 JP2023526224 A5 JP 2023526224A5 JP 2022568713 A JP2022568713 A JP 2022568713A JP 2022568713 A JP2022568713 A JP 2022568713A JP 2023526224 A5 JP2023526224 A5 JP 2023526224A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cancer
- nos
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023635P | 2020-05-12 | 2020-05-12 | |
| US63/023,635 | 2020-05-12 | ||
| US202063078747P | 2020-09-15 | 2020-09-15 | |
| US63/078,747 | 2020-09-15 | ||
| US202063114990P | 2020-11-17 | 2020-11-17 | |
| US63/114,990 | 2020-11-17 | ||
| US202063131698P | 2020-12-29 | 2020-12-29 | |
| US63/131,698 | 2020-12-29 | ||
| US202163136156P | 2021-01-11 | 2021-01-11 | |
| US63/136,156 | 2021-01-11 | ||
| PCT/US2021/032078 WO2021231639A1 (en) | 2020-05-12 | 2021-05-12 | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526224A JP2023526224A (ja) | 2023-06-21 |
| JP2023526224A5 true JP2023526224A5 (https=) | 2024-05-24 |
Family
ID=78524993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568713A Pending JP2023526224A (ja) | 2020-05-12 | 2021-05-12 | がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230174660A1 (https=) |
| EP (1) | EP4149553A4 (https=) |
| JP (1) | JP2023526224A (https=) |
| KR (1) | KR20230010221A (https=) |
| CN (1) | CN115697419A (https=) |
| AU (1) | AU2021271647A1 (https=) |
| BR (1) | BR112022022145A2 (https=) |
| CA (1) | CA3173919A1 (https=) |
| IL (1) | IL297619A (https=) |
| MX (1) | MX2022014259A (https=) |
| WO (1) | WO2021231639A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3560954T3 (pl) | 2014-04-03 | 2021-12-13 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| EP3355913B1 (en) | 2015-09-30 | 2024-10-30 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| EP4277706A1 (en) * | 2021-01-15 | 2023-11-22 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
| TW202410919A (zh) * | 2022-05-23 | 2024-03-16 | 美商英伊布里克斯公司 | Dr5促效劑與iap拮抗劑之組合療法 |
| WO2024148339A1 (en) * | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 antibody for treating cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100847010B1 (ko) * | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| WO2008066854A2 (en) * | 2006-11-28 | 2008-06-05 | Novartis Ag | Methods and compositions for inducing apoptosis in cancer cells |
| EP2303292A4 (en) * | 2008-06-09 | 2013-01-02 | New York Medical College | COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC |
| IL308212A (en) * | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| CN109476737A (zh) * | 2015-12-01 | 2019-03-15 | 根马布有限公司 | 抗dr5抗体及其使用方法 |
| EP3759229A4 (en) * | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| MX2020009069A (es) * | 2018-03-01 | 2020-10-08 | Igm Biosciences Inc | Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero. |
-
2021
- 2021-05-12 JP JP2022568713A patent/JP2023526224A/ja active Pending
- 2021-05-12 AU AU2021271647A patent/AU2021271647A1/en not_active Abandoned
- 2021-05-12 WO PCT/US2021/032078 patent/WO2021231639A1/en not_active Ceased
- 2021-05-12 US US17/998,307 patent/US20230174660A1/en active Pending
- 2021-05-12 CN CN202180031892.XA patent/CN115697419A/zh active Pending
- 2021-05-12 IL IL297619A patent/IL297619A/en unknown
- 2021-05-12 CA CA3173919A patent/CA3173919A1/en active Pending
- 2021-05-12 BR BR112022022145A patent/BR112022022145A2/pt unknown
- 2021-05-12 MX MX2022014259A patent/MX2022014259A/es unknown
- 2021-05-12 KR KR1020227042912A patent/KR20230010221A/ko active Pending
- 2021-05-12 EP EP21804501.1A patent/EP4149553A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526224A5 (https=) | ||
| ES2387809T3 (es) | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano | |
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| JP2021514945A5 (https=) | ||
| JP2008528486A5 (https=) | ||
| JP2019503349A5 (https=) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| AU2021271647A1 (en) | Use of a multimeric anti-DR5 binding molecule in combination with a cancer therapy for treating cancer | |
| EP3347054A1 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
| AU2020242144A1 (en) | Combined pharmaceutical composition for treating small cell lung cancer | |
| JP2024509018A5 (https=) | ||
| CN108350080A (zh) | 用于癌症的联合疗法 | |
| JP2023155262A (ja) | プレクチン１結合抗体およびその使用 | |
| WO2022270524A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| KR20100040884A (ko) | 화학요법제와 조합하여 암을 치료하기 위한 이뮤노사이토킨 | |
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| CN101175495B (zh) | 抗癌化合物的组合 | |
| CN120752053A (zh) | 含抗tim-3抗体的药物组合 | |
| JP2024515879A5 (https=) | ||
| CN111065412B (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
| EP4406552A1 (en) | Use of anti-cd40 antibody | |
| CN112543637B (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 | |
| HK40124723A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| Sree et al. | A review of biologic anti-cancer medicines | |
| TW202339796A (zh) | 靶向egfr之癌症療法 |